399 related articles for article (PubMed ID: 8664516)
1. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
2. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
[TBL] [Abstract][Full Text] [Related]
3. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
Pescovitz MD; Book BK; Milgrom ML; Leapman SB; Petersen B; Filo RS
Surgery; 1994 Oct; 116(4):811-8. PubMed ID: 7940183
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
7. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
8. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
Guttmann RD; Flemming C
Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin.
Fisher RA; Tchervenkov JI; Schroeder TJ; Alexander JW; Munda R; Penn I; Carey M; First MR
Transplant Proc; 1991 Feb; 23(1 Pt 2):1253-5. PubMed ID: 1989203
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
Koga A; Moreso FJ; Seron D; Gil-Vernet S; Cruzado JM; Castelao AM; Grinyó JM
Transplant Proc; 2004 Jun; 36(5):1305-7. PubMed ID: 15251318
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
Lum CT; Umen AJ; Kasiske B; Goerdt P; Heim-Duthoy KL; Andersen RC; Odland MD; Ney AL; Jacobs DM; Rao KV
Transplantation; 1995 Feb; 59(3):371-6. PubMed ID: 7871567
[TBL] [Abstract][Full Text] [Related]
13. Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival?
Farney AC; Matas AJ; Noreen HJ; Reinsmoen N; Segall M; Schmidt WJ; Gillingham K; Najarian JS; Sutherland DE
Clin Transplant; 1996 Apr; 10(2):147-56. PubMed ID: 8664509
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis.
Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson M; Heroux A; Kao W; Mullen GM; Radvany R; Robinson J
J Heart Lung Transplant; 1993; 12(5):779-89. PubMed ID: 8241215
[TBL] [Abstract][Full Text] [Related]
15. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
16. Graft outcome in cadaver renal transplants treated with full-dose cyclosporine induction without antibody, irrespective of graft function.
Douzdjian V; Bhaskar S; Baliga PK; Rajagopalan PR
Clin Transplant; 1997 Aug; 11(4):294-8. PubMed ID: 9267718
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
[No Abstract] [Full Text] [Related]
18. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
Light JA; Khawand N; Aquino A; Ali A; Korb S
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
[TBL] [Abstract][Full Text] [Related]
19. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
Cantarovich D
J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
[TBL] [Abstract][Full Text] [Related]
20. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
